Virtual Reality at End-of-life

Sponsor
State University of New York at Buffalo (Other)
Overall Status
Recruiting
CT.gov ID
NCT06149429
Collaborator
State University of New York - Upstate Medical University (Other)
40
1
1
12
3.3

Study Details

Study Description

Brief Summary

The purpose of this research is to determine the effect that repeated, personalized virtual reality experiences have on symptom severity, comparing self-reported symptom severity both pre and post each session, and overtime across sessions. We will also determine if this intervention results in a high rating of presence in VR, and if presence is related to the magnitude of the change in symptoms.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Personalized virtual reality experience
N/A

Detailed Description

The purpose of this research is to determine the effect that repeated, personalized virtual reality experiences have on symptom severity, comparing self-reported symptom severity both pre and post each session, and overtime across sessions. We will also determine if this intervention results in a high rating of presence in VR, and if presence is related to the magnitude of the change in symptoms.

H1: Symptom severity will decrease from pre-intervention to post-intervention. H2: The change in symptom severity will be greater in session two than it was in session one.

H3: Presence score will be higher in session two than session one. To recruit 30-40 participants, we will have our clinical team working to help the research team identify eligible participants from their caseloads. We will be including all hospice eligible patients, this includes people who are enrolled in hospice care but also a subset of those who are enrolled in palliative care who qualify for hospice but have refused to or haven't yet transitioned to hospice care. The site serves about 670 (as of May 2023) patients a month. Therefore, it is the researcher's intent to recruit about 3 patents per month, or a total of 30-40 patients (about 5% of the monthly population) over the course of one year.

The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to "go" to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single group open pilot, pre- post-intervention studySingle group open pilot, pre- post-intervention study
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
The Impact of a Novel Virtual Reality Protocol on Presence and Symptom Severity at the End-of-life.
Actual Study Start Date :
Nov 7, 2023
Anticipated Primary Completion Date :
Nov 6, 2024
Anticipated Study Completion Date :
Nov 6, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single-Arm Open Pilot

Pre- Post-intervention design. The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to "go" to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset.

Behavioral: Personalized virtual reality experience
The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to "go" to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset.

Outcome Measures

Primary Outcome Measures

  1. Edmonton Symptom Assessment System - Revised (ESAS) [Two weeks]

    End-of-life symptom assessment

Secondary Outcome Measures

  1. igroup presence questionnaire (IPQ) [Two weeks]

    Presence during virtual reality experience

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Healthy volunteers are not applicable to this study as they study focuses on pain and symptom management at end-of-life through the virtual reality experience.

Inclusion Criteria:
  • Patients who are hospice care eligible as defined by the Medicare Hospice benefit and receive hospice or palliative care from Hospice and Palliative Care Buffalo.
Exclusion Criteria:
  • Their Palliative Performance Score (PPS) is below 30.

  • They are not cognitively intact (display symptoms of delirium or senility, or have a cognitive diagnosis such as Alzheimer's or Dementia) as measured by the Confusion Assessment Method (CAM) (Inouye et al., 1990)

  • They have hearing, vision, or speech impairments that are uncorrected.

  • They have current symptoms of or a history of dizziness, nausea, headaches, migraines, seizures, or motion sickness.

  • They do not speak English.

  • They are not 18 years old.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospice and Palliative Care Buffalo Cheektowaga New York United States 14225

Sponsors and Collaborators

  • State University of New York at Buffalo
  • State University of New York - Upstate Medical University

Investigators

  • Principal Investigator: Catherine Mann, EdD, SUNY Buffalo

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Catherine Mann, Clinical Professor, State University of New York at Buffalo
ClinicalTrials.gov Identifier:
NCT06149429
Other Study ID Numbers:
  • STUDY00007462
First Posted:
Nov 29, 2023
Last Update Posted:
Nov 29, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Catherine Mann, Clinical Professor, State University of New York at Buffalo
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 29, 2023